MX9306005A - Combinaciones de ibupropeno-cafeina. - Google Patents

Combinaciones de ibupropeno-cafeina.

Info

Publication number
MX9306005A
MX9306005A MX9306005A MX9306005A MX9306005A MX 9306005 A MX9306005 A MX 9306005A MX 9306005 A MX9306005 A MX 9306005A MX 9306005 A MX9306005 A MX 9306005A MX 9306005 A MX9306005 A MX 9306005A
Authority
MX
Mexico
Prior art keywords
ibuprofen
ibupropen
cafeine
combinations
lisin
Prior art date
Application number
MX9306005A
Other languages
English (en)
Inventor
Robert T Sims
William Slivka
Robert Mcmahon
Original Assignee
Merck & Co Inc
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Mcneil Ppc Inc filed Critical Merck & Co Inc
Publication of MX9306005A publication Critical patent/MX9306005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas para el uso en eltratamiento de dolor e inflamación de mamíferos, incluyendo humanos aladministrar composiciones que comprenden (i) una cantidad analgésica yanti-inflamatoria de una sal de (S)-ibuprofeno substancialmente libre de(R)-ibuprofeno en las cuales la sal se selecciona de(S)-ibuprofenm-(S)-lisina y (S-ibuprofen-(R)-lisina; y (ii) una cantidad efectiva en elaumento del alivio del dolor de la cafeína.
MX9306005A 1992-09-29 1993-09-28 Combinaciones de ibupropeno-cafeina. MX9306005A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95342392A 1992-09-29 1992-09-29

Publications (1)

Publication Number Publication Date
MX9306005A true MX9306005A (es) 1995-01-31

Family

ID=25493974

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306005A MX9306005A (es) 1992-09-29 1993-09-28 Combinaciones de ibupropeno-cafeina.

Country Status (6)

Country Link
EP (1) EP0663819A4 (es)
JP (1) JPH08501796A (es)
AU (1) AU5132893A (es)
CA (1) CA2144152A1 (es)
MX (1) MX9306005A (es)
WO (1) WO1994007471A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2133733C1 (ru) * 1992-12-02 1999-07-27 Дзе бутс компани ПЛС. Способ получения фенилпропионовой кислоты
EP0717624A1 (en) * 1993-09-07 1996-06-26 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
JPH0987174A (ja) * 1995-09-26 1997-03-31 Kobayashi Pharmaceut Co Ltd 鎮痛性および抗炎症性組成物
US6251945B1 (en) * 1999-01-14 2001-06-26 Knoll Aktiengesellschaft Pharmaceutical mixture comprising a combination of a profen and other active compounds
US20090238763A1 (en) * 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
AU2015309176B2 (en) * 2014-08-28 2020-12-03 A. Nattermann & Cie. Gesellschaft mit Beshränkter Haftung Pharmaceutical composition for the treatment of acute tooth or jaw pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420483A (en) * 1982-07-22 1983-12-13 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
EP0550668A4 (en) * 1990-09-28 1993-10-13 Merck & Co. Inc. Ibuprofen-antihistamine combinations

Also Published As

Publication number Publication date
JPH08501796A (ja) 1996-02-27
WO1994007471A1 (en) 1994-04-14
EP0663819A1 (en) 1995-07-26
AU5132893A (en) 1994-04-26
EP0663819A4 (en) 1998-05-27
CA2144152A1 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
BR9406979A (pt) Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
DK0607128T4 (da) Lægemiddel samt fremstilling deraf og anvendelse deraf ved bekæmpelsen af smerter og/eller betændelser hos dyr og mennesker
ES2082288T3 (es) Composiciones terapeuticas para administracion intranasal de ketorolaco.
ES2059965T3 (es) Un procedimiento para preparar una composicion farmaceutica para el tratamiento de enfermedades inflamatorias.
ES2169197T3 (es) Composicion farmaceutica que comprende una alcanoil l-carnitina en combinacion con un acido graso poliinsaturado de la serie omega-3 para la prevencion y el tratamiento de trastornos del metabolismo de los lipidos.
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
ES2165997T3 (es) Uso de una formulacion farmaceutica pediatrica que comprende amoxicilina y clavulanato.
ES2075202T3 (es) Nuevas arilpiridazinas, su preparacion, su utilizacion, y medicamentos que las contienen.
ES2063073T3 (es) Derivados de arilmetilenilo conocidos y nuevos seleccionados de tiazolidinonas, imidazolidinonas y oxazolidinonas utiles como agentes antialergicos y agentes antiinflamatorios.
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
MX9304564A (es) Combinaciones de relajante muscular-ibuprofen.
ES2159382T3 (es) Compuestos estilbenicos con grupo adamantilo, composiciones que los contienen y utilizaciones.
ES2183841T3 (es) Formas de dosificacion para administrar un farmasco en una formulacion lquidid.
RU94002337A (ru) Фармацевтическая композиция, применение гамма-линоленовой или дигомо-гамма-линоленовой кислоты для лечения поражений после облучения, способ лечения
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
GB2075341B (en) Pharmaceutical compositions
DK165903C (da) Farmaceutisk praeparat mod acne
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
MX9306005A (es) Combinaciones de ibupropeno-cafeina.
AR025030A1 (es) Utilizacion de flupirtina para aliviar los dolores en las artropatias degenerativas en perros y gatos para la preparacion de un medicamento para eltratamiento de dichas afecciones